Lilly's Study on Higher Doses of Trulicity Meets Endpoint

Eli Lilly and Company’s LLY phase III study evaluating higher doses of its GLP-1 receptor agonist, Trulicity, demonstrated superiority in A1C (a measure of blood glucose) reduction in type II diabetes patients compared to Trulicity doses already available